EXAS - Exact Sciences Corporation Stock Trading

MADISON, Wis. , Jan. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth-quarter and full-year 2019 financial results after the close of the U.S. financial markets on Feb. 11, 2020 . Following the release, company...

I Don’t Feel Comfortable in Info and Data Tech at These Levels My go-to “fast-Money trades” are the chips, software and Internet-enabled business stocks. I understand the underlying economics, and that gives me the comfort to be aggressive when conditions call for it...

A leader in the cancer diagnostics space with a focus on early detection, Exact Sciences (NASDAQ: EXAS) had a successful 2019, with 78% year-over-year revenue growth of its key cancer screening product, Cologuard. Cologuard is a non-invasive first-line test that detects colon cancer and...